Hepatitis B: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PD-1 4
• PD-L1 2
• TP53 0
• STAT3 0
• STING 0
• CD19 0
• TNF 0
• AMPK 0
• JAK 0
• mTOR 0
• CD20 0
• EGFR 0
• ERK 0
• GPC3 0
• HIF-1 0
• IL-1 0
• IL-6 0
• PI3K 0
• PPAR 0
• TFEB 0
• ABL1 0
• AKT 0
• BCL-2 0
• CTLA-4 0
• G6PD 0
• HMGB1 0
• HSP90 0
• IL-17 0
• MYC 0
• NRF2 0
• PARP 0
• VEGF 0
• ALK 0
• AQP4 0
• ARID1A 0
• CCR5 0
• CD33 0
• CD38 0
• CD40 0
• CTNNB1 0
• FAK 0
• FGFR 0
• HDAC 0
• IL-23 0
• IL-4 0
• KRAS 0
• LAG-3 0
• MAPK 0
• METTL3 0
• MMP-9 0
• NLRP3 0
• NOTCH1 0
• PKM2 0
• PNPLA3 0
• PRMT5 0
• PSMA 0
• PTEN 0
• SGLT2 0
• TERT 0
• TIM-3 0

17 of 17+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R01

  Assessment of sound waves from liver vessels via artificial intelligence to detect liver cancer

  University of Minnesota· Minneapolis, United States· US$18,735 awarded in fiscal year 2026· until Aug 2031

• NIH NIAID · F31

  The Bifunctional Role of Interleukin-1β in Modulating Hepatitis B Virus Replication and Host Defense During HIV/HBV Coinfection

  Emory University· Atlanta, United States· US$50,114 awarded in fiscal year 2026· until Sept 2029

• NIH NHLBI · R01

  Transfusion transmitted infections and pathogen reduction technology.

  Johns Hopkins University· Baltimore, United States· US$1,084,885 awarded in fiscal year 2026· until May 2030

• NIH NIBIB · N02

  RADX INNOVATION FUNNEL FOR HEALTH TECHNOLOGIES - VALIDATION CENTER - Hep C

  Emory University· Atlanta, United States· US$5,119,273 awarded in fiscal year 2026· until Sept 2028

• NIH NIAID · R01

  Immune protection against H5N1 influenza virus infection and transmission

  Washington University· Saint Louis, United States· US$765,798 awarded in fiscal year 2026· until Aug 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Decoding Immune Aging in Chronic Hepatitis B (DECAGE)

  Universita Vita-Salute San Raffaele· Milano, Italy· EU contribution €209,483· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  Implementation of an Integrated Digital Health System for Infectious Diseases in Maternal and Child Health In East Africa (LINDA-FAMILIA)

  University College Cork - National University of Ireland, Cork· Cork, Ireland· EU contribution €4,998,563· until Jul 2029· 7 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  Innovative Point of Care for combined screening of Infectious diseases: application to Prevention of Mother to Child Transmission (MAGFA)

  Magia Diagnostics· Echirolles, France· EU contribution €5,078,816· until Dec 2027· 4 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Acquired adaptive immune cell dysfunction and restoration in chronic hepatitis B (EUCLIDEAN)

  Universita Vita-Salute San Raffaele· Milano, Italy· EU contribution €2,500,000· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-RIA

  Understanding the individual host response against Hepatitis D Virus to develop a personalized approach for the management of hepatitis D (D-SOLVE)

  Medizinische Hochschule Hannover· Hannover, Germany· EU contribution €6,754,010· until Sept 2027· 5 countries

  The disease is named only in the funder's project summary, not in the title.

10 of 264 running projects, newest first. Listed amounts together: US$216.4m + €32.5m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

• A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B

  NCT04225715· Hoffmann-La Roche· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 12
• Organoids 3
• Mendelian Randomization Analysis 7
• CRISPR-Cas Systems 23
• Gene Expression Profiling 26
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 2
• Exome Sequencing 1
• Proteomics 8
• Metabolomics 10
• Mass Spectrometry 2
• Flow Cytometry 3
• Immunohistochemistry 4
• Liquid Biopsy 2
• Xenograft Model Antitumor Assays 2
• Magnetic Resonance Imaging 22
• Machine Learning 38
• Deep Learning 6
• Cohort Studies 63
• Genome-Wide Association Study 12

• Noninvasive Diagnosis of Hepatocellular Carcinoma Outside Guideline-Defined High-Risk Populations: Evolving Perspectives in the Era of MASLD.

  Korean J Radiol, Nov 2026

• Multifactorial Contributors to Diagnostic Delay in a High-Risk Patient with Hepatocellular Carcinoma: A Case Report with Clinical Lessons.

  Int Med Case Rep J, Oct 2026

• Prognostic Implications of CT- and MRI-Based LI-RADS Category M Features in Intrahepatic Cholangiocarcinoma: An Intraindividual Comparison.

  Korean J Radiol, Sept 2026

• Characterisation of liver disease using quantitative MRI: report of the imaging arm of the ELEGANCE study.

  BMC Gastroenterol, Aug 2026

• Preoperative MRI Intratumoral Heterogeneity Radiomics for Microvascular Invasion and Recurrence-Free Survival in HCC.

  Liver Int, Aug 2026

• Case Report: Primary Central Nervous System Lymphoma With "Wine Glass" Sign Presenting as Somnolence and Fatigue.

  Am J Case Rep, Jul 2026

• Texture Analysis of Non-contrast Magnetic Resonance Imaging for Liver Fibrosis Staging in Patients with Chronic Hepatitis B.

  J Gastrointestin Liver Dis, Jul 2026

• NGS-diagnosed HBV encephalitis with isolated left parietal lobe involvement: a case report.

  Virol J, Jul 2026

• Triple primary synchronous liver cancer in one patient: the first case report and origin speculation through bioinformatics.

  World J Surg Oncol, Jun 2026

• Effect of high-intensity interval training in patients with chronic hepatitis B and hepatic steatosis: A randomised controlled trial.

  PLoS One, Jun 2026

See which targets of this disease your abstract mentions, and go to the people working on them.